These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 30530990)
21. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905 [TBL] [Abstract][Full Text] [Related]
22. Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation. Yang H; Yao Z; Zhou X; Zhang W; Zhang X; Zhang F Clin Immunol; 2020 Apr; 213():108377. PubMed ID: 32135278 [TBL] [Abstract][Full Text] [Related]
23. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691 [TBL] [Abstract][Full Text] [Related]
24. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines. Vijayakumar G; McCroskery S; Palese P J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938 [TBL] [Abstract][Full Text] [Related]
25. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review. Khan S; Gerber DE Semin Cancer Biol; 2020 Aug; 64():93-101. PubMed ID: 31330185 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity. Hu X; Bukhari SM; Tymm C; Adam K; Lerrer S; Henick BS; Winchester RJ; Mor A J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519059 [TBL] [Abstract][Full Text] [Related]
27. Time to dissect the autoimmune etiology of cancer antibody immunotherapy. Dougan M; Pietropaolo M J Clin Invest; 2020 Jan; 130(1):51-61. PubMed ID: 31895048 [TBL] [Abstract][Full Text] [Related]
28. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells. Anderson R; Theron AJ; Rapoport BL Front Immunol; 2019; 10():2254. PubMed ID: 31616428 [TBL] [Abstract][Full Text] [Related]
29. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Weinmann SC; Pisetsky DS Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080 [TBL] [Abstract][Full Text] [Related]
30. Autoimmune complications of immunotherapy: pathophysiology and management. Chan KK; Bass AR BMJ; 2020 Apr; 369():m736. PubMed ID: 32253223 [TBL] [Abstract][Full Text] [Related]
31. [Management of toxicities from immunotherapy]. Heinrich K; von Bergwelt-Baildon M; Theurich S Dtsch Med Wochenschr; 2021 Sep; 146(17):1119-1128. PubMed ID: 34448188 [TBL] [Abstract][Full Text] [Related]
32. Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors. Teng YS; Yu S Curr Oncol; 2023 Jul; 30(7):6805-6819. PubMed ID: 37504358 [TBL] [Abstract][Full Text] [Related]
33. Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Okiyama N; Tanaka R Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349 [TBL] [Abstract][Full Text] [Related]
34. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy. Sibaud V Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113 [TBL] [Abstract][Full Text] [Related]
35. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors. Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159 [TBL] [Abstract][Full Text] [Related]
36. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy. Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549 [TBL] [Abstract][Full Text] [Related]
37. Testing Immune-Related Adverse Events in Cancer Immunotherapy. Farmer JR Clin Lab Med; 2019 Dec; 39(4):669-683. PubMed ID: 31668277 [TBL] [Abstract][Full Text] [Related]
38. Functionally Masked Antibody to Uncouple Immune-Related Toxicities in Checkpoint Blockade Cancer Therapy. Song SH; Ghosh T; You DG; Joo H; Lee J; Lee J; Kim CH; Jeon J; Shin S; Park JH ACS Nano; 2023 Jun; 17(11):10065-10077. PubMed ID: 37184643 [TBL] [Abstract][Full Text] [Related]
39. The development of immunotherapy in older adults: New treatments, new toxicities? Helissey C; Vicier C; Champiat S J Geriatr Oncol; 2016 Sep; 7(5):325-33. PubMed ID: 27318796 [TBL] [Abstract][Full Text] [Related]
40. CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Yshii LM; Gebauer CM; Pignolet B; Mauré E; Quériault C; Pierau M; Saito H; Suzuki N; Brunner-Weinzierl M; Bauer J; Liblau R Brain; 2016 Nov; 139(11):2923-2934. PubMed ID: 27604307 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]